-New Data to be Presented at American Association for Cancer Research Annual Meeting-
Boulder, CO, March 26, 2019 - (GLOBE NEWSWIRE)—Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy in comparison to tissue biopsy. Two posters will be presented at the Annual Meeting of the American Association for Cancer Research in Atlanta. The abstracts can be found here.
Diagnosing Resistance to Osimertinib
The adoption of third-generation tyrosine kinase inhibitors (TKIs) to treat non-small cell lung cancer (NSCLC) for EGFR positive patients has led to acquired resistance pathways in approximately 40 percent of EGFRT790M-positive NSCLC patients. Biodesix developed a new blood-based test to detect one of the most common resistance mutations, EGFR C797S, using droplet digital PCR (ddPCR). Data shows that the Biodesix assay may be of utility in diagnosing patients who have developed resistance to osimertinib, and could save valuable time to treatment.
Development and Precision: Molecular profiling of cell-free DNA and RNA with NGS test
Lung cancer is the leading cause of cancer-related deaths in the U.S., with NSCLC being the most commonly diagnosed subtype. Liquid biopsy is increasingly utilized for non-invasive clinical testing, as 30 percent of advanced NSCLC patients are not eligible for tissue biopsy. The Biodesix process of generating molecular profiling of cell-free DNA and RNA in the blood of patients with NSCLC using next generation sequencing (NGS) was demonstrated as an effective diagnostic tool, with reduced risk to patients as compared to more invasive tissue biopsy.
“Biodesix is committed to continuing to validate and innovate across the lung cancer care continuum,” said Gary Pestano, Ph.D., Chief Development Officer for Biodesix. “There is a great amount of work to do in helping lung cancer patients find the right treatment at the right time. We are exploring technology across the field of omics to provide a complete picture of disease and available options.”
Biodesix is a lung cancer diagnostic company addressing the continuum of patient care from early diagnosis of lung nodules through late stage cancer. The company develops diagnostic tests addressing important clinical questions by combining simple blood draws and multi-omics with the power of artificial intelligence. Biodesix is the first company to offer three best-in class tests for patients with non-small cell lung cancer, and multiple pipeline tests including one with the potential to identify patients who may benefit from immunotherapies. The Biodesix Lung Reflex strategy integrates the GeneStrat® and VeriStrat® tests to support treatment decisions with results in 72 hours. The Nodify XL2™ nodule test, which will be commercially available in the second half of 2019, evaluates the risk of malignancy, enabling physicians to triage patients to the most appropriate course of action. Biodesix also partners with the world’s leading biotechnology and pharmaceutical companies to develop companion diagnostics. For more information about Biodesix, please visit www.biodesix.com.
Kena Hudson for Biodesix